medicinal market assortment
The majority of the company's revenue comes from the sale of generic drugs, but this category includes a special group of products - steroids, which provides the company with a large profit. Over the past decade, gynecological products have contributed significantly to good results, both in revenue growth and in achieving higher profit margins.
The company produces about a hundred types of pharmaceuticals in more than 170 forms. Gedeon Richter constantly updates the range, develops dosage forms and creates fundamentally new drugs.
Fig.1.
Richter distributes original drugs and conducts extensive research on compounds that act on diseases of the central nervous system.
In the company's portfolio, original drugs account for 15-20%, licensed drugs - 12% and 70-75% - branded generics.
Fig.2.
The medicinal assortment of the company is presented in 8 main areas:
1. The gynecological direction is represented by a wide range of combined oral contraceptives (COCs), drugs for emergency contraception (Postinor and Escapel), drugs for hormone replacement therapy for menopause and other drugs that are used in obstetric and gynecological practice. The CPC group is represented by both traditional and well-known Ovidon, Rigevidon and Tri-Regol, as well as modern promising drugs Novinet, Regulon, Lindinet-20, Lindinet-30 and Tristin. All PDAs manufactured by Richter Gedeon have proven to be very reliable and safe drugs for preventing unwanted pregnancy and treating gynecological pathologies. They are available for most women and come in convenient packs for both one and three cycles. Pauzogest is successfully used for hormone replacement therapy in menopause.
2. The cardiology direction is represented by a group of drugs for the treatment of arterial hypertension, heart failure and coronary heart disease. Diroton is a drug for the treatment of arterial hypertension and heart failure. This drug has a number of valuable properties that allow it to be prescribed to patients with arterial hypertension, heart failure in combination with diabetes mellitus, overweight, and liver dysfunction. A serious problem today is coronary heart disease, for the solution of which Richter Gedeon offers the drug Normodipin. For the treatment of arterial hypertension "Richter Gedeon" offers a combined drug Equator.
3. The neurological direction is represented primarily by the world famous brands Cavinton and Mydocalm - the original developments of Richter Gedeon. Thousands of neurologists, neurosurgeons, therapists, ophthalmologists, doctors of other specialties have made sure from their own clinical experience: Cavinton is a reliable friend, exactly the one that really helps in a difficult moment for their patient. As for Mydocalm, it has recently experienced a worldwide renaissance: in Germany, Japan, and many other countries, multicenter studies were conducted in compliance with the requirements of evidence-based medicine, which confirmed the high efficacy and safety of Mydocalm in the treatment of patients with pathologies of the musculoskeletal system, primarily with back pain syndrome. Rexetine (treatment of anxiety conditions), Tebantine (treatment of neuropathic pain) and Andante (hypnotic drug with a mild therapeutic profile) have become novelties on the pharmaceutical market.
4. The dermato-mycological direction is represented by both well-known preparations for external use (ointments Mycozolon, Dermazolone, Fluorocort, Aurobin), and fairly new antifungal agents - Mikosist, Terbizil, and Gynofort. Mycosist, which has 5 convenient forms of release, has established itself as an effective drug for the treatment of various types of candidiasis.
5. In the treatment of patients with gastric and duodenal ulcers, gastroesophageal reflux disease, gastritis, functional dyspepsia and other pathologies of the gastrointestinal tract, the gastroenterological drug Kvamatel (famotidine) is successfully used, and the injection form of this drug is an integral part of the effective preparation of the patient for surgery. interventions to reduce the acid-producing function of the stomach and prevent bleeding. Kvamatel and Gordox are included in the standards for the treatment of acute and exacerbations of chronic pancreatitis.
6. Urology is relatively new in the Richter Gedeon portfolio. It is represented by the drugs Tamsol and Prosterid, which are successfully used to treat benign prostatic hyperplasia, as well as the non-steroidal antiandrogen drug Kalumid for the treatment of hormone-dependent prostate cancer.
7. The hospital direction, probably, does not require a separate presentation, since medical personnel of large and small clinics, hospitals, multidisciplinary and specialized hospitals, and research institutes have been working with these drugs for several decades. The main quality criterion for Arduan, Vinblastine-Richter, Vincristine-Richter, Haloperidol, Haloperidol Decanoate, Hydrocortisone-Richter, Gordox, Calypsol, Klion d / infusion, Mycosyst d / infusion, Oxytocin, is a positive experience from the use of these drugs in a wide variety of pathologies. The predicted effect, qualitative composition and availability are the main features that enable doctors to believe in them and prescribe them to their patients again and again.
8. The direction of over-the-counter drugs (OTC) was separated into a separate direction in 2007. These drugs can be used without a doctor's prescription, and the pharmacist is the main figure on which the correctness of their use by the patient depends. This group includes Panangin, Terbizil 1% cream, Kvamatel mini dragees, Curiosin gel, Fluorocort ointment and Mycosist in capsules.
These OTC preparations are strategic in the company's portfolio and active measures are taken for them (broadcast of television advertising, publications in specialized and general publications, visits of medical representatives to pharmacies, etc.).
Fig.3.
More than 30% of the plant's products are sold in the CIS countries. Over the past years, Gedeon Richter has been a leader in the supply of medicines to Russia. The range includes about 90 drugs of various therapeutic groups.
In 2008, the share of Gedeon Richter in the Russian market was 2.3%, Russia occupies 70% of the company's total turnover in the CIS.
Among the drugs in the greatest demand in the Russian market are: Prednisolone, Postinor, Oxytocin, Mydocalm, Bromocriptine, Regulon, Novinet, Lindinet, Diroton, Normodipin, Mikosist, Terbizil and Equator.
About 40% of drugs registered in Russia are included in the Federal List of Vital and Essential Medicines. These include Normodipin, Mammozol, Bidop, Vinpocetine, Panangin, Metformin, Postinor, Veroshpiron, Retabolil and many others.
Tab. 1. Gedeon Richter's range of medicines.
|
Tradename |
INN / composition |
Pharmacotherapeutic group |
Actual number of offers |
|
obstetrics and gynecology |
|||
|
Anteovin (Anteovin) Table/set No. 63 |
|||
|
Gynofort (Gynofort) Cream vag. 2% applicators 5g |
Butoconazole (Butoconazole) |
antifungal agent |
|
|
Klion Solution for inf. 0.5% (500 mg/100 ml): vial. 100 ml. |
Metronidazole (Metronidazole) |
||
|
Klion-D 100 (Klion-D 100) Tab. vag. 100mg+100mg №10 |
metronidazole + miconazole (Metronidazole + miconazole) |
combined antimicrobial agent (antimicrobial + antifungal) |
|
|
Lactinet (Lactinette) Tab. p.p.o. 75 mcg #28 |
Desogestrel (Desogestrel) |
gestagen |
|
|
Lindynette 20 (Lindynette 20) Tab. on. 75 mcg + 20 mcg №21 |
combined contraceptive (estrogen + gestagen) |
||
|
Lindynette 20 (Lindynette 20) Tab. on. 75 mcg + 20 mcg №63 |
Gestodene + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Lindynette 30 (Lindynette 30) Tab. on. 75 mcg + 30 mcg №21 |
Gestodene + Ethinylestradiol (Gestodene + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Lindynette 30 (Lindynette 30) Tab. on. 75 mcg + 30 mcg №63 |
Gestodene + Ethinylestradiol (Gestodene + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Mycosyst Solution for inf. 2 mg/ml vial. 100 ml. #1 |
Fluconazole (Fluconazole) |
||
|
Mycosyst Caps. 150 mg #1 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg #2 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg #7 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg #28 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg #1 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg #2 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg #7 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg #28 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg #1 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg #2 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg #7 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg #28 |
Fluconazole (Fluconazole) |
broad spectrum antifungal agent |
|
|
Microfollin (Microfollin) Tab. 50 mcg #10 |
Ethinylestradiol (Ethinylestradiol) |
estrogen |
|
|
Novynette Tab. p.p.o. 150mcg+20mcg №21 |
combined contraceptive (estrogen + gestagen) |
||
|
Novynette Tab. p.p.o. 150mcg+20mcg №63 |
Desogestrel + Ethinylestradiol (Desogestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Norkolut (Norkolut) Tab. 5 mg #20 |
Norethisterone (Norethisterone) |
gestagen |
|
|
Ovidon (Ovidon) |
(Levonorgestrel + Ethinylestradiol) |
contraceptive, estrogen |
|
|
Oxytocin R-r d / in / in and / m entered. 5 IU/1 ml. amp. #5 |
Oxytocin |
labor activity stimulant - oxytocin drug |
|
|
Ostalon Tab. on. 70mg #4 |
Alendronic acid (Alendronic acid) |
bone resorption inhibitor - bisphosphonate |
|
|
Tab. p.p.o./set №32 |
|||
|
Ostalon Calcium D (Ostalon Calcium-D) Tab. p.p.o./set #96 |
Colecalciferol + calcium carbonate + alendronic acid (Colecaiciferol + calcium carbonate + alendronic acid) |
osteoporosis combined treatment (bone resorption inhibitor + calcium-phosphorus metabolism regulator + calcium drug) |
|
|
Pausogest (Pausogest) Tab. p.p.o. #28 |
|||
|
Pausogest (Pausogest) Tab. p.p.o. №28*3 |
Norethisterone + Estradiol (Norethisterone + Estradiol) |
combined anti-menopausal agent (estrogen + gestagen) |
|
|
Postinor (Postinor) Tab. 0.75 mg #2 |
gestagen |
||
|
Regulon Tab. p.p.o. 150mcg+30mcg №21 |
Desogestrel + Ethinylestradiol (Desogestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Regulon Tab. p.p.o. 150mcg+30mcg №63 |
Desogestrel + Ethinylestradiol (Desogestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon (Rigevidon) Tab. on. 150 mcg + 30 mcg №21 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon (Rigevidon) Tab. on. 150 mcg + 30 mcg №63 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon 21+7 Tab. on. 30 mcg + 150 mcg №28 |
Levonorgestrel + Ethinylestradiol Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon 21+7 (Rigevidon 21+7) Tab. on. 30 mcg + 150 mcg №28*3 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Triaklim Tab. p.p.o. No. 28 and 28 * 3 |
Norethisterone + Estradiol (Norethisterone + Estradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Tri-regol (Tri-regol) Tab. on. #21 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen. |
|
|
Tri-regol (Tri-regol) Tab. on. #63 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Tab.p.o. #28 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Tri-regol 21+7 (Tri-regol 21+7) Tab.p.o. №28*3 |
Levonorgestrel + Ethinylestradiol (Levonorgestrel + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Escapelle Tab. 1.5 mg #1 |
Levonorgestrel (Levonorgestrel) |
gestagen |
|
|
Estrimax (Estrimax) Tab. p.p.o. 2 mg No. 28 |
Estradiol (Estradiol) |
||
|
Estrimax (Estrimax) Tab. p.p.o. 2mg #28*3 |
Estradiol (Estradiol) |
Anticlimacteric estrogen drug |
|
|
Anesthesiology |
|||
|
Calypsol (Calypsol) Solution for injections. 500 mg/10 ml: vial. #5 |
Ketamine |
drug for anesthesia |
|
|
Sombrevin Solution d / in. 5 %; amp. 10 ml №5 |
Propanidid (Propanidid) |
drug for anesthesia |
|
|
Fentanyl (Fentanyl) Solution d / in. 0.05 mg/ml. amp. 10 ml No. 50 |
Fentanyl (Fentanyl) |
analgesic (opioid) drug |
|
|
Gastroenterology |
|||
|
Vermox Tab. 100 mg #6 |
Mebendazole (Mebendazole) |
anthelmintic |
|
|
Histodyl (Histodyl) Solution d / in. 200 mg/2 ml; amp. 2 ml №10 |
Cimetidine (Cimetidine) |
antiulcer |
|
|
Histodyl (Histodyl) Tab. 0.2 g №50 |
Cimetidine (Cimetidine) |
antiulcer |
|
|
Decaris (Decaris) Tab. 50 mg #1 |
Levamisole (Levamisole) |
anthelmintic |
|
|
Decaris (Decaris) Tab. 50 mg #2 |
Levamisole (Levamisole) |
anthelmintic |
|
|
Decaris (Decaris) Tab. 150 mg #1 |
Levamisole (Levamisole) |
anthelmintic |
|
|
Decaris (Decaris) Tab. 150 mg #2 |
Levamisole (Levamisole) |
anthelmintic |
|
|
Kvamatel (Quamatel) Tab. p.p.o. 20 mg #14 |
Famotidine (Famotidine) |
||
|
Kvamatel (Quamatel) Tab. p.p.o. 20 mg #28 |
Famotidine (Famotidine) |
a drug that lowers the secretion of the gastric glands - H2-histamine receptor blocker |
|
|
Kvamatel (Quamatel) Tab. p.p.o. 40 mg #14 |
Famotidine (Famotidine) |
a drug that lowers the secretion of the gastric glands - H2-histamine receptor blocker |
|
|
Kvamatel (Quamatel) Lioft d / prepared. r-ra d / in / in the input. 20 mg bottle No. 5 in set. with solution |
Famotidine (Famotidine) |
a drug that lowers the secretion of the gastric glands - H2-histamine receptor blocker |
|
|
Kvamatel (Quamatel) Tab. p.p.o. 40 mg #14 |
Famotidine (Famotidine) |
a drug that lowers the secretion of the gastric glands - H2-histamine receptor blocker |
|
|
Kvamatel mini (Quamatel mini) Tab. p.p.o. 10 mg #14 |
Famotidine (Famotidine) |
a drug that lowers the secretion of the gastric glands - H2-histamine receptor blocker |
|
|
Klion Tab. 250 mg #20 |
Metronidazole (Metronidazole) |
antimicrobial and antiprotozoal agent |
|
|
Nifuroxazide-Richter Nifuroxazide-Richter Susp. for oral administration 220 mg/5 ml vial. 90 ml per set with dosing spoon |
Nifuroxazide |
||
|
Nifuroxazide-Richter Nifuroxazide-Richter Tab. p. p. o. 100 mg No. 24 |
Nifuroxazide |
Intestinal antiseptic. Antidiarrheal drug |
|
|
Omeprazole-Richter (Omeprazol-Richter) Caps. 20 mg #14 |
Omeprazole (Omeprazole) |
antiulcer |
|
|
Sirepar Solution d / in.; fl. 10 ml №5 |
hepatoprotector |
||
|
Dermatology |
|||
|
Dermozolon (Dermosolon) Ointment for external approx. 5mg+30mg/1g 5g |
Clioquinol + Prednisolone (Clioquinol + Prednisolone) |
glucocorticosteroid in combination |
|
|
Curiosin (Curiosin) Gel 1% 15 g. |
tissue repair stimulator |
||
|
Mycosolone (Mycosolon) Ointment for external approx. 15 g |
Mazipredone + Miconazole (Mazipredone + Miconazole) |
antifungal agent |
|
|
Terbizil (Terbisil) Cream for external use approx. 1% 15g |
Terbinafine (Terbinafine) |
antifungal agent |
|
|
Terbizil (Terbisil) Tab. 125 mg #14 |
Terbinafine (Terbinafine) |
antifungal agent |
|
|
Terbizil (Terbisil) Tab. 125 mg #28 |
Terbinafine (Terbinafine) |
antifungal agent |
|
|
Terbizil (Terbisil) Tab. 250 mg #14 |
Terbinafine (Terbinafine) |
antifungal agent |
|
|
Terbizil (Terbisil) Tab. 250 mg #28 |
Terbinafine |
antifungal agent |
|
|
Fluorocort (Ftorocort) Ointment for external approx. 0.1% 15g |
Triamcinolone (Triamcinolone) |
Glucocorticosteroid for external use appl. |
|
|
Immunology |
|||
|
Avonex (Avonex) Liof. d / r-ra d / w / m introduced. 30 mcg |
Interfero beta-1a (Interferon beta-1a) |
Interferon preparation |
|
|
Groprinosin (Groprinosin) Tab. 500 mg #50 |
Inosine pranobex (Inosine pranobex) |
Immunostimulating drug |
|
|
Clargotil (Clargotil) Syrup 5 mg/5 ml 120ml |
Loratadine (Loratadine) |
||
|
Clargotil (Clargotil) Tab. 10 mg #10 |
Loratadine (Loratadine) |
antiallergic agent - H1-histamine receptor blocker |
|
|
Lordestin Tab. p.p.o. 5mg. #10 |
Desloratadine (Desloratadine) |
antiallergic agent - H1-histamine receptor blocker |
|
|
Lordestin Tab. p.p.o. 5mg. #30 |
Desloratadine (Desloratadine) |
antiallergic agent - H1-histamine receptor blocker |
|
|
Filergim (Filergim) Solution d / in / in and s / c injections of 30 million IU, syringes 1 ml. #1 |
Filgrastim (Filgrastim) |
leukopoiesis stimulant |
|
|
Filergim (Filergim) Solution d / in / in and s / c injections 48 million IU, syringes 0.5 ml. #1 |
Filgrastim (Filgrastim) |
leukopoiesis stimulant |
|
|
Cardiology |
|||
|
Bidop (Bidop) Tab. 5 mg #14 |
Bisoprolol (Bisoprolol) |
||
|
Bidop (Bidop) Tab. 5 mg #28 |
Bisoprolol (Bisoprolol) |
selective beta1-blocker |
|
|
Bidop (Bidop) Tab. 5 mg #56 |
Bisoprolol (Bisoprolol) |
selective beta1-blocker |
|
|
Bidop (Bidop) Tab. 10 mg #14 |
Bisoprolol (Bisoprolol) |
selective beta1-blocker |
|
|
Bidop (Bidop) Tab. 10 mg #28 |
Bisoprolol (Bisoprolol) |
selective beta1-blocker |
|
|
Bidop (Bidop) Tab. 10 mg #56 |
Bisoprolol (Bisoprolol) |
selective beta1-blocker |
|
|
Verospiron (Verospiron) Tab.25mg. #20 |
|||
|
Verospiron (Verospiron) Caps. 50mg #30 |
Spironolactone (Spironolactone) |
diuretic potassium sparing agent |
|
|
Verospiron 9Verospiron) Caps.100mg. #30 |
Spironolactone (Spironolactone) |
diuretic potassium sparing agent |
|
|
Heparin-Richter (Heparin-Richter) Solution d / in. 25000 IU/5 ml; fl. 5 ml |
Heparin sodium (Heparin sodium) |
anticoagulant |
|
|
Digoxin (Digoxin) Tab. 0.25 mg №50 |
Digoxin (Digoxin) |
cardiotonic agent - cardiac glycoside |
|
|
Diroton Tab. 2.5 mg #14 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 2.5 mg #28 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 2.5 mg #56 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 5 mg #14 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 5 mg #28 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 5 mg #56 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 10 mg #14 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 10 mg #28 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 10 mg #56 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 20 mg #14 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 20 mg #28 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Diroton Tab. 20 mg #56 |
Lisinopril (Lisinopril) |
ACE inhibitor |
|
|
Tab. p.p.o. 50 mg #10 |
Losartan (Losartanum) |
||
|
Losartan Richter Tab. p.p.o. 50 mg #30 |
Losartan (Losartanum) |
angiotensin II receptor antagonist |
|
|
Losartan Richter Tab. p.p.o. 100 mg #10 |
Losartan (Losartanum) |
angiotensin II receptor antagonist |
|
|
Losartan Richter Tab. p.p.o. 100 mg #30 |
Losartan (Losartanum) |
angiotensin II receptor antagonist |
|
|
Losartan-N Richter (Lazartan-N Richter) Tab. p.p.o. 12.5 mg + 50 mg №30 |
|||
|
Tab. p.p.o. 12.5 mg + 100 mg №30 |
Losartan + Hydrochlorothiazide (Losartanum + hydrochlorothiazide) |
combined antihypertensive agent (angiotensin II receptor antagonist + diuretic) |
|
|
Losartan-N Richter 9Lazartan-N Richter) Tab. p.p.o. 25 mg + 100 mg №30 |
Losartan + Hydrochlorothiazide (Losartanum + hydrochlorothiazide) |
combined antihypertensive agent (angiotensin II receptor antagonist + diuretic) |
|
|
Co-Diroton (Co-Diroton) Tab. 12.5 mg + 10 mg #10 |
Hydrochlorothiazide + Lisinopril |
||
|
Co-Diroton (Co-Diroton) Tab. 12.5 mg + 10 mg №30 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive agent (ACE inhibitor + diuretic) |
|
|
Co-Diroton (Co-Diroton) Tab. 12.5 mg + 20 mg #10 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive agent (ACE inhibitor + diuretic) |
|
|
Co-Diroton (Co-Diroton) Tab. 12.5 mg + 20 mg №30 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive agent (ACE inhibitor + diuretic) |
|
|
Mertenil (Mertinil) Tab. p.p.o. 5 mg №30 |
Rosuvastatin (Rosuvastatin) |
||
|
Mertenil (Mertinil) Tab. p.p.o. 10 mg #30 |
Rosuvastatin (Rosuvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Mertenil (Mertinil) Tab. p.p.o. 20 mg #30 |
Rosuvastatin (Rosuvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Mertenil (Mertinil) Tab. p.p.o. 40 mg #30 |
Rosuvastatin (Rosuvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Normodipin (Normodipine) Tab. 5 mg. #10 |
Amlodipine (Amlodipine) |
||
|
Normodipin (Normodipine) Tab. 5 mg. #30 |
Amlodipine (Amlodipine) |
calcium channel blocker |
|
|
Normodipin (Normodipine) Tab. 10 mg. #10 |
Amlodipine (Amlodipine) |
calcium channel blocker |
|
|
Normodipin (Normodipine) Tab. 10 mg. #30 |
Amlodipine (Amlodipine) |
calcium channel blocker |
|
|
Nortivan Tab. p.p.o. 40 mg #30 |
Valsartan (Valsartan) |
angiotensin II receptor antagonist |
|
|
Nortivan Tab. p.p.o. 80 mg #30 |
Valsartan (Valsartan) |
angiotensin II receptor antagonist |
|
|
Nortivan Tab. p.p.o. 160 mg #30 |
Valsartan |
angiotensin II receptor antagonist |
|
|
Panangin Tab. p.p.o. 158mg.+140mg. #50 |
potassium and magnesium preparation |
||
|
Panangin R-r d / in / in the introduction. 452 mg + 400 mg / 10 ml amp. #5 |
Potassium and magnesium aspartate (Potassium aspartate and magnesium aspartate) |
potassium and magnesium preparation |
|
|
Predizin (Predizin) Tab. on. 20 mg #30 |
Trimetazidine (Trimetazidine) |
antihypoxant |
|
|
Predizin (Predizin) Tab. retard p.o. 35 mg #60 |
Trimetazidine (Trimetazidine) |
antihypoxant |
|
|
Roglit Tab. on. 2mg. №60 |
Rosiglitazone (Rosiglitazone) |
||
|
Roglit Tab. on. 4 mg. №30 |
Rosiglitazone (Rosiglitazone) |
oral hypoglycemic agent |
|
|
Roglit Tab. on. 4mg.#60 |
Rosiglitazone (Rosiglitazone) |
oral hypoglycemic agent |
|
|
Roglit Tab. on. 8 mg. №30 |
Rosiglitazone (Rosiglitazone) |
oral hypoglycemic agent |
|
|
Simvastol Tab. p.p.o. 10 mg #14 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 10 mg #28 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 20 mg #14 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 20 mg #28 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 40 mg #14 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 40 mg #28 |
Simvastatin (Simvastatin) |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Ednit (Ednyt) Tab. 2.5 mg #20 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 2.5 mg #100 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 5 mg #20 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 5 mg №100 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 10 mg #20 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 10 mg #100 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 20 mg #20 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Ednit (Ednyt) Tab. 20 mg #100 |
Enalapril (Enalapril) |
ACE inhibitor |
|
|
Equator Tab. 5 mg + 10 mg №10 |
|||
|
Equator Tab. 5 mg + 10 mg №20 |
Amlodipine + Lisinopril (Amlodipin + Lisinopril) |
combined antihypertensive agent (ACE inhibitor + BMCC) |
|
|
Equator Tab. 5 mg + 10 mg №30 |
Amlodipine + Lisinopril (Amlodipin + Lisinopril) |
combined antihypertensive agent (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg + 20 mg №10 |
Amlodipine + Lisinopril (Amlodipin + Lisinopril) |
combined antihypertensive agent (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg + 20 mg №30 |
Amlodipine + Lisinopril (Amlodipin + Lisinopril) |
combined antihypertensive agent (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg + 20 mg №60 |
Amlodipine + Lisinopril (Amlodipin + Lisinopril) |
combined antihypertensive agent (ACE inhibitor + BMCC) |
|
|
Neurology and Psychiatry |
|||
|
Andante Caps. 5mg #7 |
Zaleplon |
hypnotic |
|
|
Andante Caps. 5mg #14 |
Zaleplon |
hypnotic |
|
|
Andante Caps. 10mg #7 |
Zaleplon |
hypnotic |
|
|
Andante Caps. 10mg #14 |
Zaleplon |
hypnotic |
|
|
Vinpocetine Tab. 5 mg No. 50 |
Vinpocetine |
||
|
Haloperidol (Haloperidol) Tab. 1.5mg #25 |
Haloperidol (Haloperidol) |
||
|
Haloperidol (Haloperidol) Tab. 1.5mg #50 |
Haloperidol (Haloperidol) |
antipsychotic (neuroleptic) |
|
|
Haloperidol (Haloperidol) Tab. 5mg #25 |
Haloperidol (Haloperidol) |
antipsychotic (neuroleptic) |
|
|
Haloperidol (Haloperidol) Tab. 5mg #50 |
Haloperidol (Haloperidol) |
antipsychotic (neuroleptic) |
|
|
Haloperidol (Haloperidol) Solution d / in / in and / m vved.5mg / 1ml amp. #5 |
Haloperidol (Haloperidol) |
antipsychotic (neuroleptic) |
|
|
Haloperidol decanoate (Haloperidol decanoate) Solution d / w / m entered. (oily) 50 mg/1 ml: amp. #5 |
Haloperidol (Haloperidol) |
antipsychotic (neuroleptic) |
|
|
Droperidol (Droperidol) Solution for injections. 25 mg/10 ml: vial. #50 |
Droperidol (Droperidol) |
antipsychotic |
|
|
Cavinton Conc. d/prep. r-ra d / inf. 5 mg/ml: amp. 2 ml. #10 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton Conc. d/prep. r-ra d / inf. 5 mg/ml: amp. 10 ml №5 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton Tab. 5 mg #50 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Tab 10 mg №30 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton forte (Cavinton forte) Tab 10 mg №90 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Lamolep (Lamolep) Tab. 25mg.#10 |
Lamotrigine (Lamotrigine) |
||
|
Lamolep (Lamolep) Tab. 50mg.#10 |
Lamotrigine (Lamotrigine) |
antiepileptic drug |
|
|
Lamolep (Lamolep) Tab. 100mg. №10 |
Lamotrigine (Lamotrigine) |
antiepileptic drug |
|
|
Lamolep (Lamolep) Tab. 25mg.#30 |
Lamotrigine (Lamotrigine) |
antiepileptic drug |
|
|
Lamolep (Lamolep) Tab. 50mg.#30 |
Lamotrigine (Lamotrigine) |
antiepileptic drug |
|
|
Lamolep (Lamolep) Tab. 100mg. №30 |
Lamotrigine (Lamotrigine) |
antiepileptic drug |
|
|
Mydocalm-Richter (Mydocalm-Richter) Solution d / iv and IM injections 100 mg + 2.5 mg / ml No. 5 |
Lidocaine + Tolperisone (Lidocaine + Tolperisone) |
||
|
Mydocalm (Mydocalm) Tab. p.p. about 50 mg No. 30 |
Tolperisone (Tolperisone) |
centrally acting muscle relaxant |
|
|
Mydocalm (Mydocalm) Tab. p.p. about 150 mg No. 30 |
Tolperisone (Tolperisone) |
centrally acting muscle relaxant |
|
|
Nantarid Tab. p.p.o. 25 mg #30 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 25 mg #60 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 100 mg #30 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 100 mg #60 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 200 mg #30 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 200 mg #60 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 300 mg #30 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 300 mg #60 |
Quetiapine (Quetiapine) |
antipsychotic (neuroleptic) |
|
|
Tab. p.p.o. 400 mg #20 |
Piracetam (Piracetam) |
nootropic |
|
|
Piracetam-Richter (Pyracetam-Richter) Tab. p.p.o. 800 mg #20 |
Piracetam (Piracetam) |
nootropic |
|
|
Rexetin (Rexetin) Tab. p.p.o. 20 mg #10 |
Paroxetine (Paroxetine) |
antidepressant |
|
|
Rexetin (Rexetin) Tab. p.p.o. 20 mg #30 |
Paroxetine (Paroxetine) |
antidepressant |
|
|
Rexetin (Rexetin) Tab. p.p.o. 30 mg #10 |
Paroxetine (Paroxetine) |
antidepressant |
|
|
Rexetin (Rexetin) Tab. p.p.o. 30 mg #30 |
Paroxetine (Paroxetine) |
antidepressant |
|
|
Ridonex (Ridonex) Tab. p.p.o. 1 mg №20 |
Risperidone (Risperidone) |
antipsychotic (neuroleptic) |
|
|
Ridonex (Ridonex) Tab. p.p.o. 2 mg #20 |
Risperidone (Risperidone) |
antipsychotic (neuroleptic) |
|
|
Ridonex (Ridonex) Tab. p.p.o. 4 mg #20 |
Risperidone (Risperidone) |
antipsychotic (neuroleptic) |
|
|
Seduxen (Seduxen) Tab. 5 mg #20 |
Diazepam (Diazepam) |
||
|
Seduxen (Seduxen0 Solution d / in / in and / m vved.5 mg / ml amp. 2 ml. #5 |
Diazepam (Diazepam) |
anxiolytic agent (tranquilizer) |
|
|
Stugeron Tab. 25 mg #50 |
Cinnarizine (Cinnarizine) |
drug that improves cerebral blood flow |
|
|
Tebantin (Tebantin) Caps. 100 mg #10 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 100 mg #50 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 100 mg #100 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 300 mg #10 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 300 mg #50 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 300 mg #100 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 400 mg #10 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) caps. 400 mg #50 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Tebantin (Tebantin) Caps. 400 mg #100 |
Gabapentin (Gabapentin) |
antiepileptic drug |
|
|
Framex (Framex) Caps. 20 mg No. 14 and 28 |
Fluoxetine (Fluoxetine) |
antidepressant |
|
|
Eunoctin (Eunoctin) Tab. 10 mg #10 |
Nitrazepam (Nitrazepam) |
hypnotic |
|
|
Oncology |
|||
|
Vinblastin-Richter (Vinblastin-Richter) Liof. d/prep. r-ra d / in / in the input. 5 mg vial No. 10 in set. with solution |
Vinblastine (Vinblastine) |
||
|
Wincristine-Richter Vincristine-Richter Liof. d / r-ra for / in the input. 1 mg with solution fl. No. 10 |
Vincristine (Vincristine) |
antitumor agent - alkaloid |
|
|
Mammosole (Mammosole) Tab. p.p.o. 1 mg №28 |
Anastrozole (Anastrozole) |
antitumor agent - estrogen synthesis inhibitor |
|
|
Calumid (Calumid) Tab.p.p.o. 50mg. #30 |
Bicalutamide (Bicalutamide) |
||
|
Calumid (Calumid) Tab.p.p.o. 50mg. #90 |
Bicalutamide (Bicalutamide) |
anticancer agent - antiandrogen |
|
|
Calumid (Calumid) Tab.p.p.o. 150mg. #30 |
Bicalutamide (Bicalutamide) |
anticancer agent - antiandrogen |
|
|
Emetron Solution for injections. 4 mg/2 ml amp. #5 |
Ondansetron (Ondansetron) |
||
|
Emetron Solution for injections. 8 mg/4 ml amp. #5 |
Ondansetron (Ondansetron) |
antiemetic - serotonin receptor antagonist |
|
|
Emetron Tab. on. 4 mg #10 |
Ondansetron (Ondansetron) |
antiemetic - serotonin receptor antagonist |
|
|
Emetron Tab. on. 8 mg #10 |
Ondansetron (Ondansetron) |
antiemetic - serotonin receptor antagonist |
|
|
Pediatrics |
|||
|
Suprax (Suprax) Gran. d/prep. susp. d / ingestion 100 mg / 5 ml: vial. 60 ml |
Cefixime (Cefixime) |
3rd generation cephalosporin |
|
|
Suprax (Suprax) Caps. 200 mg #6 |
Cefixime (Cefixime) |
3rd generation cephalosporin |
|
|
Suprax (Suprax) Caps. 400 mg #6 |
Cefixime (Cefixime) |
3rd generation cephalosporin |
|
|
Proctology |
|||
|
Aurobin (Aurobin) Ointment for rectal and external. appl. 20 y. |
Prednisolone capronate + lidocaine hydrochloride + D-panthenol (Dexpanthenol + Lidocaine + Prednisolone) |
glucocorticosteroid agent combined for topical application |
|
|
Rheumatology |
|||
|
Airtal Tab. on. 100 mg #20 |
Aceclofenac (Aceclofenac) |
||
|
Airtal Tab. on. 100 mg #30 |
Aceclofenac (Aceclofenac) |
||
|
Airtal Tab. on. 100 mg #40 |
Aceclofenac (Aceclofenac) |
||
|
Airtal Tab. on. 100 mg #60 |
Aceclofenac (Aceclofenac) |
||
|
Butadion (Butadion) Ointment for external approx. 5% 20g |
Phenylbutazone (Phenylbutazone) |
||
|
Depersolone (Depersolon) Solution for injections. 30 mg/1 ml: amp. Number 3 |
Mazipredone (mazipredone) |
glucocorticosteroid |
|
|
Mirloks (Mirlox) Tab.p.o. 15mg.#20 |
Meloxicam (Meloxicam) |
||
|
Mirloks (Mirlox) Tab.p.o. 2.5mg.#20 |
Meloxicam (Meloxicam) |
||
|
Prednisolone (Prednisolone) Tab.5mg №100 vial. p / propyl. |
Prednisolone (Prednisolone) |
glucocorticosteroid |
|
|
Urology |
|||
|
Prosterid (Prosterid) Tab. p.p.o. 5 mg. №14 |
Finasteride (Finasteride) |
5-alpha reductase inhibitor |
|
|
Prosterid (Prosterid) Tab. p.p.o. 5 mg. №28 |
Finasteride (Finasteride) |
5-alpha reductase inhibitor |
|
|
Sonizin (Sonizin) Caps. with mod. release 0.4mg. #10 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Sonizin (Sonizin) Caps. with mod. release 0.4mg. #30 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Tamsol Caps. with mod. release 0.4 mg №30 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Surgery |
|||
|
Arduan (Arduan) Liof. d/prep. solution for d / in / in the introduction of 4 mg fl. No. 25 in set. with solvent |
|||
|
Arduan (Arduan) Liof. d/prep. solution for d / in / in the introduction of 4 mg fl. No. 5 in set. with solvent |
Pipecuronium bromide (Pipecuronium bromide) |
muscle relaxant non-depolarizing peripheral action. |
|
|
Gordox (Gordox) Conc. d/prep. r-ra d / in / in the input. 100 thousand CIE / 10 ml amp. No. 25 pcs. |
Aprotinin (Aprotinin) |
fibrinolysis inhibitor - a polyvalent inhibitor of plasma proteinases. |
|
|
Klion Solution for inf. 0.5% (500 mg/100 ml): vial. #1 |
Metronidazole (Metronid)azole |
antimicrobial and antiprotozoal agent |
|
|
Curiosin (Curiosin) R-r d / ext. approx. 2.05 mg/1 ml vial 10 ml with dropper |
Zinc hyaluronate (Zinc hyaluronate) |
tissue repair stimulator |
|
|
Endocrinology |
|||
|
Bromocriptin-Richter (Bromocriptin-Richter) Tab. 2.5 mg #30 |
Bromocriptine B(romocriptine) |
dopamine receptor agonist |
|
|
Hydrocortisone-Richter (Hydrocortison-Richter) Susp. d / in / sust. and okolosust. input. 25 mg+5 mg/ml vial 5 ml. No. 1 |
Hydrocortisone + Lidocaine (Hydrocortisone + Lidocaine) |
glucocorticosteroid |
|
|
Tab. p.p.o. 500 mg #20 |
Metformin (Metformin) |
||
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 500 mg #30 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 500 mg #40 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 500 mg #60 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 850 mg #20 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 850 mg #30 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 850mg #40 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Metformin-Richter (Metformin-Richter) Tab. p.p.o. 850mg #60 |
Metformin (Metformin) |
hypoglycemic agent for oral use of the biguanide group |
|
|
Donalgin (Donalgin) Caps. 250 mg #30 |
Niflumic acid |
||
|
Retabolil (Retabolil) Solution d / w / m. input. [oily] 50 mg/ml amp. 1 ml №1 |
Nandrolone (Nandrolone) |
anabolic steroid drug |
There are 30 national, inter-regional and regional distributors on the pharmaceutical wholesale market of the Voronezh region involved in the supply of medicinal products.
The product range, or rather its completeness, is of great socio-economic importance, since its quality determines the completeness of satisfaction of consumer demand. A narrow assortment can be one of the factors hindering the process of meeting the individual needs of each consumer. Determining the optimal assortment is a key moment in the economic activity of each pharmacy organization and allows you to ensure the maximum economic efficiency of its activities. For the marketing characteristics of the assortment, the assortment completeness ratio was calculated, which is calculated as the ratio of the number of assortment positions produced by the company and available on the market (actual completeness) to the number of assortment positions registered in Russia and offered by suppliers.
KP=Pfact/Pbaz
where KP is the coefficient of completeness of the assortment;
Pfakt - actual completeness;
Pbaz - base fullness.
The basic completeness is 260 drugs, taking into account different packaging and dosage. 166 positions were found in supplier firms, respectively, CP = 0.64 or 64% of drugs, which allows us to conclude that the studied company Gedeon Richter is not sufficiently present on the regional drug market.
In the pharmacy, the assortment of this company is represented by 67 positions, as a result of which the CP is 0.4 or 40% of drugs relative to the offers of supplier firms, which indicates a low presence ratio in the retail link of medicines of the studied company Gedeon Richter.
In order to determine the change in the assortment of Richter medicines, the entry of new medicines into the Russian pharmaceutical market was studied. For this purpose, the renewal coefficient was calculated:
KO=Ofact/Obaz
where, KO - renewal coefficient;
Ofakt - the number of drugs that appeared on the regional market during the study period;
Obaz - base quantity of drugs available on the regional market.
Of the 12 trade names of Gedeon Richter, registered in Russia over the past five years, 10 items entered the market, i.е. Ko = 10/12 or 0.83.
The renewal coefficient for the medicines of this company was 0.83, which is a fairly high figure, indicating the active introduction of new drugs to the pharmaceutical market.
The largest number of assortment positions of drugs is presented for the treatment of diseases of the cardiovascular and central nervous systems, as well as for drugs that serve to preserve the reproductive health of women.
JSC "Gedeon Richter" is one of the largest pharmaceutical manufacturers in Eastern Europe. The company has mastered the production of 200 types of drugs, a fifth of which are its own unique developments.
Way to success
The first pharmacy "Gedeon Richter" earned in 1901 in the Hungarian Budapest. At that time, pharmacists themselves prepared medicinal drugs. A laboratory was equipped at the pharmacy, where the production of organotherapeutic drugs produced from extracts of the glands of cattle was organized.
After 6 years, the first plant was launched, the production of lecithins, vitamins and other components was launched. Later they mastered the processing of plant materials: derivatives of salicylic acid appeared. By the way, the drug "Calmopyrin", mastered in 1912, is still used today. By 1914, Gedeon Richter had patented 24 drugs, becoming a strategic pharmaceutical enterprise in Austria-Hungary.
The pill that changed the world
With the beginning of the "era of contraception" in the 60s, many associate such a phenomenon as a significant change in the social status of women in society. Contraceptives allowed 100% to prevent unplanned pregnancy.
It was the outstanding pharmacist from Budapest, Gedeon Richter, who stood at the origins of hormonal synthesis and worked on the first contraceptive pill. The production of gynecological preparations was started from the very foundation of the company in 1901, together with the development of the first organotherapeutic preparations. In 1939, the company developed a technology for isolating estrone, and set up industrial production of crystalline estrone. The creation of synthetic testosterone and progesterone consolidated the success.
"Gedeon Richter": preparations
In the 1950s, a key compound for hormone synthesis was created, used to produce sex hormones (progesterone, estrone, and testosterone), non-steroidal anabolic agents, and oral contraceptives.
Since the early 1960s, Gedeon Richter has been using the most modern production technologies, including sterile fermentation. Later, thanks to new technologies, it became possible to manufacture new active substances, such as norgestrel, levonorgestrel and their derivatives, resulting in the creation of a combined hormonal contraceptive, released in 1966. The firm also brought hormonal contraception to the USSR for the first time.
Now fourth-generation drugs have appeared, which, for example, contain drospirenone as an active ingredient. Being a synthetic hormone, it is similar to progesterone produced by the body.
Quality
Production control and compliance with all advanced standards are of paramount importance in the production of hormonal preparations. Simply put, it is important to understand exactly how and under what technological conditions hormonal preparations are synthesized in order to boldly talk about the quality of the product and minimize undesirable effects. In the world, a few large concerns have their own synthesis of sex steroids. The pharmaceutical industry is armed with high-performance liquid chromatography, nuclear magnetic resonance and other high-tech assistants.
Substances for the manufacture of drugs and the hormonal components themselves are produced in Hungary, which allows you to trace all stages of production and be sure of the result. It is this quality and approach that doctors and patients trust, as well as scientists from those countries where the company supplies its famous substances.
Development
Today, intellectual capital is a key factor in determining the weight of a company, so leading companies need to invest in R&D (research and development). For the pharmaceutical business, this means that research and development activities in the field of developing new products and practical solutions become the core of development. It is noteworthy that Gedeon Richter is the only Eastern European company that entered the TOP-200 in the innovation spending category with an indicator of 12% of annual turnover.
In 2010, the joint-stock company bought out the Swiss biopharmaceutical company Preglem. It offers molecules for the treatment of complex gynecological diseases such as uterine fibroids, endometriosis, and others.
"Gedeon Richter-Rus"
The company produces about two hundred types of drugs in more than 400 forms of release. As part of the strategy for the future, it was decided in 1996 to establish a separate production facility in Central Russia. Hungarian pharmacists built one of the five subsidiaries in the Yegoryevsky district near Moscow. It releases:
- finished medications;
- intermediate connections;
- active substances.
Thus, Gedeon Richter-Rus became the first foreign pharmaceutical company in Russia. Today, the plant provides not only the domestic market, but also exports medicines to the CIS countries (Georgia, Armenia, Moldova, Azerbaijan).
For the benefit of society
The current situation involves the joint work of scientists - pharmacists and physicians for the benefit of society. Gedeon Richter initiates and supports events of various levels in Russia:
- scientific and practical conferences;
- seminars, congresses;
- international forums.
The task of maintaining women's reproductive health should be addressed at all levels. Following this logic, Gedeon Richter regularly carries out educational and other supportive activities for the professional community. For example, Hungarian pharmacists have been sponsoring the Reproductive Tomorrow of Russia award for many years. The award winners make an invaluable contribution to the development of the Russian school of obstetrics and gynecology.
"Gedeon Richter" has a scientific base at the level of the highest world standards, its own scientific developments have allowed the company to significantly expand the range of gynecological preparations. A wide selection helps professionals and women make important decisions in their lives, while the quality and assortment of hormonal contraceptives continues to improve.
1901 - Gedeon Richter acquired the pharmacy Shash (Oryol) in Budapest, which belongs to the company to this day. He founded a biological laboratory for chemical experiments and began to produce and market tonics and various organotherapeutic hormones.
1902 - Gedeon Richter's first product - Tonogen Suprarenal.
1906 - The company is founded on an area of 1000 sq. m. on Zirkassian Street and is the basis for the modern pharmaceutical industry in Hungary. A factory was built on the same site.
1907 - The plant began to produce medicines on an industrial scale. The first drugs produced at the plant included disinfectants, antipyretics and painkillers, one of the most famous - Kalmopyrin (acetylsalicylic acid) is used to this day.
1914 - 28 preparations of the Gedeon Richter plant are patented.
1920 - about 150 types of drugs are already on the market. The experience gained from the development of these drugs is successfully applied by the Company, providing an even greater variety of products in the domestic market.
1930 - Gedeon Richter becomes one of the leaders in the production of Estrone in the world. By the end of the year, the Company opens 10 representative offices. At the same time, the Company begins an in-depth study and development of synthetic drugs.
Between the two world wars, the Company had 10 subsidiaries, 40 overseas offices and a network on five continents. At the end of World War II, Gedeon Richter became one of Hungary's largest exporters.
1949 - the creation of the CMEA, the plant "Gedeon Richter" focuses its production on the market of the CMEA member countries. All export-import transactions within the CMEA are carried out centrally through the state foreign trade enterprise Medimpex.
1950s - Along with an increase in the volume of export operations during this period, a research direction is developing, work is underway to create steroid hormonal preparations. Several original drugs have been developed and patented.
1960s - technical re-equipment of the enterprise, strengthening of the research base.
1968 - The company establishes a new advanced pharmacology center where a number of developments are carried out under the guidance of experts.
1974 - a new drug Cavinton enters the market, one of the most successful products of the Company.
After 1992, the Gedeon Richter company was corporatized. Creation of own market network and a network of representative offices in various countries of the world.
1995 - September 8 - the decision of the management of the company "Gedeon Richter" to create an organized market network in the CIS countries.
XXI century - the eastern part of Central Europe with a market network on five continents. About 100 countries receive the plant's products. OJSC "Gedeon Richter" has 29 representative offices in 31 countries, 38 commercial and wholesale enterprises, 5 manufacturing enterprises, not including Hungarian plants (Russia, Romania, Poland, Germany, India). The unique market network covers the EU countries, the USA, the CIS countries, Japan and the eastern region. OJSC "Gedeon Richter" is a regional multinational enterprise.
